A New Horizon in Gene EditingIn the rapidly evolving field of genetic medicine, a groundbreaking development has emerged with the…
Browsing: News
We mourn the profound loss of Dr. Krystal Cascetta, a committed oncologist and breast cancer researcher. Our hearts extend to…
Cody Peer, PhD, from the National Institutes of Health, is conducting a randomized research study comparing the dosing intervals of…
Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area Anthony Tolcher MD By Anthony Tolcher, MD One of…
Martin S. Tallman, MD from Weill Cornell and Sloan Kettering discusses Martin S. Tallman, MD, Begins Term as 2021 ASH…
DUBLIN – January 27, 2021 – Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan’s Ministry of Health, Labour and Welfare…
Benjamin Tycko, MD of Hackensack Meridian Health explains his study findings on DNA that Pinpoint Risks for Cancers. By sequencing…
Benjamin Tycko, MD of Hackensack Meridian Health explains Classical Cancer Epigenetic vs Epigenetic Mapping. By sequencing entire genomes for DNA…
Benjamin Tycko, MD gives an overview of Signposts in DNA that Pinpoint Risks for Cancers and other Diseases. By sequencing…
J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health…
J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health…
J. Marie Suga MD @jmsuga of Kaiser Permanente Northern California discusses implementing a genomic oncology program in an integrated health…
Company completes CLIA Validation of DetermaIOâ„¢, previously the Insight Genetics IM Score Test, establishing the test as a reliable and robust…
Collaboration combines Harbour BioMed’s proprietary H2L2 Harbour Mice® platform for fully human monoclonal antibody generation with Mount Sinai’s translational medical research…
NCCN celebrates 25th anniversary year; shares updates from oncology experts on leading-edge cancer management practices during NCCN 2020 Annual Conference in…
Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment…
Caregiving responsibilities found to negatively affect academic productivity, primarily for men Hematologists who complete a mentored training program experience greater…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Longeveron LLC, a leading developer of adult stem cell technologies for aging-related and life-threatening conditions, announced today that it has…
Immunomedics has developed an antibody drug conjugate (ADC) called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to triple negative breast…
National Comprehensive Cancer Network to address HPV-related cancer prevention and treatment with World Cancer Day fundraiser and at upcoming NCCN…
Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different…
Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type…
– Improved clinical outcomes in advanced gastric/gastroesophageal junction cancer patients with DKK1-high tumors when treated with DKN-01 and anti PD-1…
Today, the American Society of Hematology (ASH) released new clinical practice guidelines on Sickle Cell Disease (SCD)-Related Transfusion Support. These…
The American Society of Hematology (ASH) is pleased to announce that Gabriela Hobbs, MD, of Massachusetts General Hospital, and Oluwatoyosi…
Data to include early analyses of Stivarga® (regorafenib) across HCC, CRC and GI cancers, including Phase 1b data in combination…
Patrick Therasse, MD of Servier Group discusses Servier’s R&D efforts in oncology.
First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate and Actionable Genomic Information to Oncology…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the…
Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial Clinical Data Presentation and…
More central line-associated blood infections and catheter malfunctions seen with PICCs A new study provides convincing evidence that the use…
Andrew Campbell, MD of Children’s National Hospital discusses the CASiRE study.
Jan G. J. van de Winkel, Ph.D of @Genmab announces data to be presented at ASH 2019 including data from…
David Gilham, MD of Celyad discusses a human NKG2D receptor-based CAR-T cell that potentially targets 80% of all cancers.
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more…
Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual…
The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at…
— The Leukemia & Lymphoma Society (LLS) and the American Society of Hematology (ASH) announced today a collaboration to expand access to LLS’s unique…
Kymab, a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody-based therapeutics, today announced that abstracts describing two lead hematology programs,…
Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic…
Atlanta Falcons and Atlanta United owner Arthur Blank’s gift is his second to Mount Sinai’s Department of Urology The Milton…
Today, ASH published new state-of-the art guidelines on the treatment of immune thrombocytopenia (ITP), a rare blood disorder characterized by…
A new collaborative study led by Cleveland Clinic and University Hospitals has found that commonly used clinical indicators of immune…
Soricimed Biopharma Inc. (“Soricimed”), a clinical-stage pharmaceutical company developing first-in-class, targeted cancer therapeutics, today announced that a review of recent work…
Gabriela Chiosis of @sloan_kettering explains the importance of paradigms for precision medicine in cancer therapy. __________ Read here:Â https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30427-1#%20
Gabriela Chiosis, of @sloan_kettering discusses paradigms for precision medicine in epichaperome cancer therapy. _______ Read here:Â https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30427-1#%20 Also Recomended: Synthesis of…
  Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new data will be presented on the efficacy…
Philadelphia, PA (Nov. 19, 2019) – Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of…
Patients show improvements in blood vessels and physical ability after 8-week regimen — While exercise offers benefits for a wide range…
Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent…
Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple…
Ayman A. Saad, MD of @OSUCCC_James answers commonly asked questions regarding the @NCCN guidelines debut to manage complications and actually…
Ayman A. Saad, MD of @OSUCCC_James discusses the @NCCN guidelines debut to manage complications and actually improve readiness for stem…
— First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in…
National Comprehensive Cancer Network expands resources to meet growing utilization of cell-based cancer treatments. Today, the National Comprehensive Cancer Network® (NCCN®)…
A comparison of the Pinktober and Movember movements reveals that reach and engagement do not always lead people to research…
Company Commences First-in-Human Study at Multiple Academic Sites in United States Oct. 29, 2019 /PRNewswire/ — Linnaeus Therapeutics, Inc. (Linnaeus),…
Evidence from the lead program showed that glucocorticoids promote the growth of prostate tumor cells, stimulate androgen-regulated gene expression and…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM describes what is next and how this protein associated with many disease is visualized…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM answers common questions involving a protein associated with many disease is visualized for the…
Steven Mansoor, MD @mansoor_steven of @OHSUSOM explains a protein associated with many disease is visualized for the first time. ___________…
New drugs can be motivated by understanding how receptors of P2X7 proteins function. Scientists first noticed how a protein associated…
(WASHINGTON, October 3, 2019) — Yesterday, ASH President Roy Silverstein, MD, of the Medical College of Wisconsin asked members of the United…
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions considers the future of artificial intelligence being used by…
Bruce Feinberg DO, VP Chief Medical Officer, Cardinal Health Specialty Solutions expresses some concerns surrounding artificial intelligence.
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions comments on how artificial intelligence may evolve into a…
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions discusses how artificial intelligence can increase efficiency and be…
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions showcases real-world examples of artificial intelligence being used by…
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions explains the misunderstanding and complexity of artificial intelligence and…
Joan Brugge PhD Of Harvard Medical School Discusses The Process Of Tumor Genesis & Tumor Cells Response To Therapy: Its…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Questions About mRNA: Takes 50-60 Days From Biopsy To…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses How Did The Patients Do: Out Of 13 Patients…
Tal Zaks MD, PhD, Chief Medical Officer at Moderna Therapeutics Discusses Emerging Data For Personalized Vaccine Approach: Safety Profile Was…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Why Is CBX-11 Data Significant: Our Platform Technology Is Specific & Only Delivers…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses When Will CBX-11 Enter The Clinic: Clinical Program Starting In January Or February…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses What Is Alphalex & How Does It Work: Makes Use Of Acidic Tumor…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Strategy Of Alphalex Developement: The Agnostic Nature Of The Platform Allows Us To…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses How Is Alphalex Different: Its An Antigen Agnostic Tumor Targeting Technology, Can Target…
Vishwas Paralkar, PhD Of Cybrexa Therapeutics Discusses Cybrexa Additional Candidates: CBX-11 Is The First Of Many Candidates, More Data Will…
Armon Sharei PhD Of SQZ Biotech Discusses Trial Addressing HPV Positive Tumors: Enrolling Patients In Trial This Year, Looking At…
Armon Sharei PhD Of SQZ Biotech Discusses SQZ Biotech: Engineer Multiple Facets Of Cell Function In A Very Practical Way,…
Armon Sharei PhD Of SQZ Biotech Discusses Questions About SQZ Biotech Technology: Use SQZ Platform To Deliver Antigens Directly Into…
Omid Hamid MD @OmidHamidMD Of The Angeles Clinic Discusses ASCO 2019 Data: Many Approvals In Solid Tumors, Responses In Patients…
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda In Depth, Enhancing Chemo & Radiotherapies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyonda & Isoflavonoid Studies.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Veyondas Future In NSCLC, Sarcomas & Prostate Cancer.
Greg Van Wyk Noxopharm Chief Medical Officer Discusses Developing Isoflavone Idronoxil For Oncology Purposes.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Engineering EBV Specific T cells.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Mesothelin Targeted CAR-T Study.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses EBV CD19 CAR-T Cells Potency.
Christopher Haqq M.D., PhD Executive Vise President Of Atara Biotherapeutics Discusses Subset Of 11 Mesothelioma Patients.
Vishwas Paralkar PhD, Cybrexa Chief Scientific Officer Discusses Combining Alphalex Technology With Rucaparib.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses What IRAK4 Degredation Offers.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses The Future Of The IRAK4 Degrader.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Protein Degradation Technology.
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses Elaborating On The IRAK4 Protein Degrader
Laurent Audoly PhD, CEO Of Kymera Therapeutics Discusses E3 Ligase Atlas In Development.
Rena Feinman, PhD Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center Discusses The Microboime…
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses AstraZeneca The Leader In Hematology At The 60th ASH…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Xofigo Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Stivarga Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Regorafenib Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Copanlisib Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Larotrectinib Program. At ESMO Oncology Conference -…
Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Whats on The Horizon For Bayer Pharmaceuticals. At…
Scott Fields, SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Larotrectinib, Xofigo, Copanlisib, & Regorafenib Research. At ESMO Oncology…
Scott Fields, SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Treatment With Xofigo, Abiraterone, & Copanlisib. At ESMO Oncology…
Thomas Helleday, Phd, Helleday Laboratory, Discusses Using Mutational Signatures To Tailor New Treatments. At ESMO Oncology Conference – Munich, Germany…
Francis J. McGovern, MD explains the need to Educate to Patients to Only Take What is Needed | Pain Level…
Francis J. McGovern, MD explains Blocking Inflammatory Pain Pathway | Anesthetic Depends on Expertise of Anesthesiologist at AACR 2018
Francis J. McGovern, MD explains the Perioperative Opioid-Sparing Analgesia Strategies for Enhanced Recovery after Urologic Surgery at AACR 2018
Jon Eckard, MD, TYME Inc., explains Explosion of Development Over Last 5-10 Years | Focus on the Patients Not Just…
Petros Grivas, MD, PhD, University of Washington talks about Academic & Community Oncologists Must Collaborate | Accrue Trials to Develop…
Eric A. Klein, MD, Cleveland Clinic explains No Good Screening Tests for Several Cancers | Able to See Early Signals…
Eric A. Klein, MD, Cleveland Clinic, explains Tumor Cells Shed DNA & RNA | Technology Is Powerful Enough to Find…
Eric A. Klein, MD, Cleveland Clinic, Preliminary Look at 10% of 15,000 Participants | Not Ready to be Applied to…
Eric A. Klein, MD, Cleveland Clinic, explains how Test Must Have High Specificity | False-Positive Rate Must be Extraordinarily Low…
Liviu Niculescu, MD PhD, explains How To Make Sense of the Amount of Information Focus on the Most Important Data…
Rafael G Amado, MD, Adaptimmune, LLC, explains Engineer T-Cell Receptors, Affinity Matured Can recognize and kill tumor cells at Annual…
Jon Eckard, PhD, TYME Inc., explains Patients Tired of Toxic Chemotherapies Current data shows efficacy & maintaining quality of life…
Rafael G Amado, MD, Adaptimmune, LLC, explains Expanding Cohorts of Patients to Verify Results Increase number of cells & intensity…
Jon Eckard, PhD, TYME Inc., explains Studies Today are Focused on Biomarkers Not Biomarker specific, broad efficacy at Annual Meeting…
Jon Eckard, PhD, TYME Inc., talks about Four Drug Combination – effects driven by one drug With other drugs supplementing…
Rafael G Amado, MD, Adaptimmune, LLC, explains Between 1-5 Billion Cells Given to Patients Cytokine Release Syndrome resolved with antiIL-6…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about Data is Hypothesis-Generating Data is still useful for determining optimal…
Chuck Wiseman, MD, BriaCell Therapeutics, discusses Capitalizing on Matching HL-Antigens Key to developing clinically relevant immune response at Annual Meeting…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains BTK Inhibitors Associated with Atrial Fibrillation Only 4%…
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Ibrutinib & Rituximab is a new standard for…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Genome Sequencing Enable a Complete Picture Additional analyses not found on…
Chinthalapally V. Rao, PhD, Stephenson Cancer Center, talks about Marginal Beneficial Effects After 6 Months to 1 Year Limitations of…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Researchers Upload Data With St. Jude Cloud Goal is to Enable…
Scott Newman, PhD, St. Jude Children’s Research Hospital, explains What is St. Jude Cloud? Bring tools to the data &…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Access, Analyze, & Visualize Genomic Data Offer 5,000 Genome sequencing datasets…
Chinthalapally V. Rao, PhD, Stephenson Cancer Center, talks about Aspirin Prevents Colorectal Cancer Progress Patients subconsciously taking aspirin may cause…
Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Examples of Genes Activated by Enhancer Hijacking Validate findings based…
Scott Newman, PhD, St. Jude Children’s Research Hospital, explains St. Jude Cloud Reanalyzed coding variants Some B-Cell ALL have mutational…
Jinghui Zhang, PhD, St. Jude Children’s Research Hospital, explains Cloud-Computing – Centralized Infrastructure Enables access of data for all research…
Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Linking Aberrations to Oncogene De-Regulation Unable to make 1-to-1 correlation…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about MD Anderson Provides Screenings for Therapies Reviewed by Precision Oncology…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Next Meeting will Showcase Modern Technology Next generation sequencing…
Paul A. Northcott, PhD, St. Jude Children’s Research Hospital, explains Novel Mechanisms of Oncogene De-Regulation Integrative Genomic Approaches to implicate…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about Understanding Intratumor Heterogeneity Founding ubiquitous mutations vs. heterogeneous events at…
Emily L. Harris, Ph.D., M.P.H., National Cancer Institute – Deputy Associate Director, explains Three Main Data Sharing Policies Large Budget…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, talks about Abnormalities With Next-Gen Sequencing Widen therapeutic options by tailoring trials…
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, explains 80% of Patients Don’t go to Tertiary Centers Making sure…
Emily L. Harris, Ph.D., M.P.H.,National Cancer Institute – Deputy Associate Director, explains NIH Data Sharing Accelerates Research Progress Sharing broadly…
Timothy Yap, MBBS, Ph.D., MD Anderson Cancer Center, explains TRK-Inhibitor, Larotrectinib Can administer to patients with TRK-fusions at AACR 2018.
Elaine R. Mardis, PhD, The Institute for Genomic Medicine, talks about Big Shoes to Fill as President of AACR Association…
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and…